Literature DB >> 15681406

Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.

Donald N Forthal1, Gary Landucci, Tran B Phan, Juan Becerra.   

Abstract

Antibodies can prevent lentivirus infections in animals and may play a role in controlling viral burden in established infection. In preventing and particularly in controlling infection, antibodies likely function in the presence of large quantities of virus. In this study, we explored the mechanisms by which antibodies neutralize large inocula of human immunodeficiency virus type 1 (HIV-1) on different target cells. Immunoglobulin G (IgG) from HIV-infected patients was tested for neutralizing activity against primary R5 strains of HIV-1 at inocula ranging from 100 to 20,000 50% tissue culture infective doses. At all virus inocula, inhibition by antibody was enhanced when target cells for virus growth were monocyte-depleted, peripheral blood mononuclear cells (PBMCs) rather than CD4(+) lymphocytes. However, enhanced inhibition on PBMCs was greatest with larger amounts of virus. Depleting PBMCs of natural killer (NK) cells, which express Fc receptors for IgG (FcgammaRs), abrogated the enhanced antibody inhibition, whereas adding NK cells to CD4(+) lymphocytes restored inhibition. There was no enhanced inhibition on PBMCs when F(ab')(2) was used. Further experiments demonstrated that the release of beta-chemokines, most likely through FcgammaR triggering of NK cells, contributed modestly to the antiviral activity of antibody on PBMCs and that antibody-coated virus adsorbed to uninfected cells provided a target for NK cell-mediated inhibition of HIV-1. These results indicate that Fc-FcgammaR interactions enhance the ability of antibody to neutralize HIV-1. Since FcgammaR-bearing cells are always present in vivo, FcgammaR-mediated antibody function may play a role in the ability of antibody to control lentivirus infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681406      PMCID: PMC546539          DOI: 10.1128/JVI.79.4.2042-2049.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count.

Authors:  D N Forthal; G Landucci; B Keenan
Journal:  AIDS Res Hum Retroviruses       Date:  2001-04-10       Impact factor: 2.205

2.  Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE.

Authors:  J Rönnelid; A Tejde; L Mathsson; K Nilsson-Ekdahl; B Nilsson
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

3.  Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Authors:  R Hofmann-Lehmann; J Vlasak; R A Rasmussen; B A Smith; T W Baba; V Liska; F Ferrantelli; D C Montefiori; H M McClure; D C Anderson; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; H Katinger; G Stiegler; L A Cavacini; M R Posner; T C Chou; J Andersen; R M Ruprecht
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.

Authors:  V Lafont; J Liautard; J P Liautard; J Favero
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

5.  Human immunodeficiency virus in semen and plasma: investigation of sexual transmission risk behavioral correlates.

Authors:  S C Kalichman; M Cage; T Barnett; P Tharnish; D Rompa; J Austin; W Luke; J O'Mowrey; R F Schinazi
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

Review 6.  Inflammation in autoimmunity: receptors for IgG revisited.

Authors:  H M Dijstelbloem; J G van de Winkel; C G Kallenberg
Journal:  Trends Immunol       Date:  2001-09       Impact factor: 16.687

7.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.

Authors:  John R Mascola; Mark K Louder; Christine Winter; Ranjani Prabhakara; Stephen C De Rosa; Daniel C Douek; Brenna J Hill; Dana Gabuzda; Mario Roederer
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

10.  Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.

Authors:  Maria Liljefors; Bo Nilsson; Anna-Lena Hjelm Skog; Peter Ragnhammar; Håkan Mellstedt; Jan-Erik Frödin
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

View more
  26 in total

1.  Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.

Authors:  Christopher J Miller; Meritxell Genescà; Kristina Abel; David Montefiori; Donald Forthal; Kristen Bost; Jun Li; David Favre; Joseph M McCune
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 2.  Is developing an HIV-1 vaccine possible?

Authors:  Barton F Haynes; Hua-Xin Liao; Georgia D Tomaras
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 3.  New paradigms for HIV/AIDS vaccine development.

Authors:  Louis J Picker; Scott G Hansen; Jeffrey D Lifson
Journal:  Annu Rev Med       Date:  2011-09-19       Impact factor: 13.739

Review 4.  Role of Fc-mediated antibody function in protective immunity against HIV-1.

Authors:  George K Lewis
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

5.  In vitro inhibition of HIV-1 replication in autologous CD4+ T cells indicates viral containment by multifactorial mechanisms.

Authors:  Ting Tu; Jianbo Zhan; Danlei Mou; Wei Li; Bin Su; Tong Zhang; Tao Li; Ning Li; Hao Wu; Cong Jin; Huabiao Chen
Journal:  Virol Sin       Date:  2017-09-15       Impact factor: 4.327

Review 6.  Role of humoral immunity in host defense against HIV.

Authors:  Linda L Baum
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

7.  Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Authors:  M Anthony Moody; Hua-Xin Liao; S Munir Alam; Richard M Scearce; M Kelly Plonk; Daniel M Kozink; Mark S Drinker; Ruijun Zhang; Shi-Mao Xia; Laura L Sutherland; Georgia D Tomaras; Ian P Giles; John C Kappes; Christina Ochsenbauer-Jambor; Tara G Edmonds; Melina Soares; Gustavo Barbero; Donald N Forthal; Gary Landucci; Connie Chang; Steven W King; Anita Kavlie; Thomas N Denny; Kwan-Ki Hwang; Pojen P Chen; Philip E Thorpe; David C Montefiori; Barton F Haynes
Journal:  J Exp Med       Date:  2010-04-05       Impact factor: 14.307

8.  Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

Authors:  Cherie T Ng; J Pablo Jaworski; Pushpa Jayaraman; William F Sutton; Patrick Delio; LaRene Kuller; David Anderson; Gary Landucci; Barbra A Richardson; Dennis R Burton; Donald N Forthal; Nancy L Haigwood
Journal:  Nat Med       Date:  2010-10-03       Impact factor: 53.440

9.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

10.  Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody.

Authors:  Ilnour Ourmanov; Takeo Kuwata; Robert Goeken; Simoy Goldstein; Ranjani Iyengar; Alicia Buckler-White; Bernard Lafont; Vanessa M Hirsch
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.